Non-Small-Cell Lung Cancer | China In-Depth | China | 2023
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably, most therapies in development target patients with activating EGFR mutations, which are more common in China than the Western markets. We anticipate that China’s NSCLC therapy market will expand rapidly over the 2022-2032 forecast period. Key market drivers include the launch and continued uptake of targeted and biomarker-driven therapies (e.g., Hansoh Pharma’s Ameile, Betta’s Bemena, Roche’s Alecensa) in metastatic patients and their expected label expansions to the early-stage setting. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL)—will influence the launch and uptake of new therapies during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this highly lucrative market.
Questions Answered
- What is the diagnosed incidence of NSCLC, and how are these patients treated today? Do treatment management strategies differ between urban and rural China?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of NSCLC?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content Highlights
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of non-small-cell lung cancer (NSCLC) in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 20+ drugs; Phase II: 20+ drugs; coverage of select preclinical and Phase I products.
Product Description
China-In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
